Management of Diarrhea in Breast Cancer | Priority Report

Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer

August 16, 2019

Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.

Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast Cancer

May 08, 2019

Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).

Prophylaxis Regimens Reduce Neratinib-Associated Diarrhea in HER2+ Breast Cancer

May 04, 2019

A loperamide prophylactic regimen with or without the addition of either budesonide or colestipol in patients with HER2-positive early breast cancer who received treatment with neratinib (Nerlynx) led to a significant reduction in incidence and severity of diarrhea.